23 May 2022
The draft guidance describes the benefit-risk principles used to conduct product quality-related assessments of CMC information submitted to FDA for assessment as part of NDAs, BLAs, or supplements.
FDA published draft guidance on May 9, 2022 that describes the benefit-risk principles the agency applies when conducting product quality-related assessments of chemistry, manufacturing, and controls information it receives as part of new drug applications (NDAs), biologics license applications (BLAs), and supplements to drug approval applications. Data and supporting information are submitted to the agency by sponsors to demonstrate a drug product’s identity, strength, quality, and purity. FDA assesses this information to determine if an “applicant’s product development studies, manufacturing process, and control strategy will consistently result in a finished product of acceptable quality when manufactured at the facilities named in the application.”
FDA considers the overall benefits and risks of the product when deciding to approve a product application. Benefit-Risk Considerations for Product Quality Assessments details how the agency assesses these risks, the sources of uncertainty, and mitigation strategies. Unresolved product quality issues, and how they may be addressed, are also discussed in the document.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024